Comparison of Gadobutrol and Gadofosveset Tridodium in MRI for Rectal Cancer.

Congress:

ECR 2018

Poster Number:

C-1612

Type:

Scientific Exhibit

Keywords:

Experimental, MR-Diffusion/Perfusion, Colon, Gastrointestinal tract, Contrast agents, Contrast agent-intravenous, Cancer

Authors:

R. A. P. Dijkhoff¹, S. drago², J. Santinha³, D. M. J. Lambregts⁴, J. J. M. van Griethuysen⁴, F. C. Bakers¹, N. Papanikolaou³, R. G. H. Beets-Tan⁴, M. Maas⁴; ¹Maastricht/NL, ²MONZA/IT, ³Lisbon/PT, ⁴Amsterdam/NL

DOI:

10.1594/ecr2018/C-1612

DOI-Link:

https://dx.doi.org/10.1594/ecr2018/C-1612

Table 1: Gadobutrol versus gadofosveset trisodium

Fig. 1: Signal intensity time curves for all gadobutrol patients.

Fig. 2: Signal intensity time curves for all gadofosveset trisodium patients.

Aims and objectives

Normal 0 21 false false false NL X-NONE X-NONE Gadolinium based contrast agents (GBCAs) have been a crucial part of MR imaging for the last two decades for many diseases. GBCAs cause a reduction of T1 relaxation resulting an increased signal intensity (SI) improving the visualisation of pathological tissue.[1, 2] One well studied technique which uses GBCAs is dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) which makes a series of dynamic images before, during and after intravenous injection of the contrast agent. DCE-MRI has shown...

Methods and materials

Normal 0 21 false false false NL X-NONE X-NONE Patient population: Dynamic contrast-enhanced MRI with gadofosveset trisodium (Ablavar®, Lantheus Medical Imaging, Billerica, MA, North American and Australian rights) was used for research in rectal cancer. Rectal cancer patients were retrospectively selected from a dataset of patients who had DCE-MRI for (re)staging which was approved by the local institutional review board.[15] For comparison of enhancement characteristics a small group of similar patients underwent DCE-MRI with gadobutrol (Gadovist®, Schering AG, Berlin, Germany) with the same DCE-MRI protocol....

Results

Normal 0 21 false false false NL X-NONE X-NONE 12 patients were included, 6 were scanned with GDB and 6 with GDF. The GDB group had a mean age of 73 years (SD 11 years) and 66.7% were male patients. The GDF group had a mean age of 65 years (SD 16 years) of which 66.7% were male patients. The clinical tumour and nodal staging was identical in both groups, respectively cT1-2 50.0%, cT3 33.3% and cT4 16.7%, and cN0 33.3%, cN1 33.3% and cN2...

Conclusion

Normal 0 21 false false false NL X-NONE X-NONE The aim of this study was to compare the signal intensity time curves of GDF with that of GDB in DCE-MRI in patients with rectal cancer. In this small exploratory study, the albumin-binding contrast agent GDF showed similar contrast uptake parameters when compared to GDB, while the wash-out phase differed between both groups. Our results suggest that the contrast agents behave similarly during the uptake phase. This can probably be explained by the fact that shortly...

Personal information

References

Normal 0 21 false false false NL X-NONE X-NONE References 1. Scott LJ (2013) Gadobutrol: A review of its use for contrast-enhanced magnetic resonance imaging in adults and children. Clin Drug Investig 33:303–314. 2. Tweedle M, Kanal E, Muller R (2014) Considerations in the Selection of a New Gadolinium-Based Contrast Agent. Appl Radiol 3. Woolf DK, Padhani AR, Taylor NJ, Gogbashian A, Li SP, Beresford MJ, Ah-See ML, Stirling J, Collins DJ, Makris A (2014) Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance...